Johns Hopkins ABX Guide
Letermovir
INDICATIONS
FDA
FDA
- Prophlyaxis of cytomegalovirus infection (CMV) in patients (> 18 years of age) who are CMV-seropositive and have undergone an allogeneic stem cell transplant
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: June 6, 2018
Citation
Dzintars, Kathryn. "Letermovir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2018. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540691/all/Letermovir.
Dzintars K. Letermovir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540691/all/Letermovir. Accessed November 21, 2024.
Dzintars, K. (2018). Letermovir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540691/all/Letermovir
Dzintars K. Letermovir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. [cited 2024 November 21]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540691/all/Letermovir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Letermovir
ID - 540691
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2018/06/06/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540691/all/Letermovir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
